Israeli firm BiondVax, a biopharmaceutical company developing a Universal Flu Vaccine, has been awarded $1.34 million from Israel’s Chief Scientist in the Ministry of Economy to promote the company’s efforts at holding a Phase III trial for the vaccine.
BiondVax will also use the award money to improve the manufacturing process of the vaccine and prepare for its scale up for when it comes time to commercialize it.
BiondVax’s Universal Flu Vaccine, M-001 was designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. The company states that its technology utilizes a proprietary combination of conserved and common epitopes from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
BiondVax has successfully completed two Phase II and two Phase I/II clinical trials of the lead product, the Multimeric-001 Universal Flu Vaccine. According to the company, in all four trials, the vaccine was shown to be safe and immunogenic, successfully stimulating both humoral and cellular immune responses.
Pre-clinical and clinical results support that Multimeric-001 is a universal flu vaccine that in the event of a pandemic could be administered as a pandemic primer, to prepare the population immunologically while the pandemic strain-specific vaccine is manufactured.
“We are proud to have been awarded yet another grant by the OCS. In the last years OCS has expressed its repeated trust in our Universal Vaccine program and we enjoyed considerable financial support that led to our clinical successes, ” Ron Babecoff, BiondVax’ CEO, said in a statement. “This is another step in our journey to approve the first universal flu vaccine.”
BiondVax was co-founded in 2003 by Dr. Ron Babecoff.